JP2013538831A - Ｃ型肝炎ウィルス感染治療のための四環式インドール誘導体 - Google Patents
Ｃ型肝炎ウィルス感染治療のための四環式インドール誘導体 Download PDFInfo
- Publication number
- JP2013538831A JP2013538831A JP2013530529A JP2013530529A JP2013538831A JP 2013538831 A JP2013538831 A JP 2013538831A JP 2013530529 A JP2013530529 A JP 2013530529A JP 2013530529 A JP2013530529 A JP 2013530529A JP 2013538831 A JP2013538831 A JP 2013538831A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- membered
- independently
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 CC1N(*)**(C)(*)C1 Chemical compound CC1N(*)**(C)(*)C1 0.000 description 67
- QINBOYLGTAFNET-UHFFFAOYSA-N Bc(cc1)cc2c1[nH]c(-c1ccc(C)cc1O)c2 Chemical compound Bc(cc1)cc2c1[nH]c(-c1ccc(C)cc1O)c2 QINBOYLGTAFNET-UHFFFAOYSA-N 0.000 description 1
- IJTQCSODXNWQJO-UHFFFAOYSA-N C(C1)CNC1c1ncc(C(C2)C=Cc3c2cc-2[n]3C(c3cc(-c4ccccc4)ccc3)Oc3c-2ccc(-c2cnc(C4NCCC4)[nH]2)c3)[nH]1 Chemical compound C(C1)CNC1c1ncc(C(C2)C=Cc3c2cc-2[n]3C(c3cc(-c4ccccc4)ccc3)Oc3c-2ccc(-c2cnc(C4NCCC4)[nH]2)c3)[nH]1 IJTQCSODXNWQJO-UHFFFAOYSA-N 0.000 description 1
- HUSLRIJPTPGLJJ-RQZCQDPDSA-N C/C(/c(ccc(Br)c1)c1O)=N\Nc(cc1)ccc1Br Chemical compound C/C(/c(ccc(Br)c1)c1O)=N\Nc(cc1)ccc1Br HUSLRIJPTPGLJJ-RQZCQDPDSA-N 0.000 description 1
- BWJPJZKPDIMUMD-NSHDSACASA-N C=CC(O[C@@H](c1ccccc1)N)=C Chemical compound C=CC(O[C@@H](c1ccccc1)N)=C BWJPJZKPDIMUMD-NSHDSACASA-N 0.000 description 1
- POQUGTGMDLNVKU-VIFPVBQESA-N C=CC(c1cnc([C@H]2NCCC2)[nH]1)=C Chemical compound C=CC(c1cnc([C@H]2NCCC2)[nH]1)=C POQUGTGMDLNVKU-VIFPVBQESA-N 0.000 description 1
- TZMVSNSCBJDOQF-UHFFFAOYSA-N CBC(CC1=C2c3cc(cc(cc4)Cl)c4[N]3(-c3ccccc3)O1)C=C2F Chemical compound CBC(CC1=C2c3cc(cc(cc4)Cl)c4[N]3(-c3ccccc3)O1)C=C2F TZMVSNSCBJDOQF-UHFFFAOYSA-N 0.000 description 1
- PEVCXEBLFFEPGE-JTQLQIEISA-N CC(C)(C)OC(N(CC(C)(C)C1)[C@@H]1C1NC=CN1)=O Chemical compound CC(C)(C)OC(N(CC(C)(C)C1)[C@@H]1C1NC=CN1)=O PEVCXEBLFFEPGE-JTQLQIEISA-N 0.000 description 1
- IMAIYZZQVVKONO-VIFPVBQESA-N CC(C)(C)OC(N1[C@H](CO)CC(C)(C)C1)=O Chemical compound CC(C)(C)OC(N1[C@H](CO)CC(C)(C)C1)=O IMAIYZZQVVKONO-VIFPVBQESA-N 0.000 description 1
- GJKQGMCYPJTRFU-QMMMGPOBSA-N CC(C)/N=C(/[C@H]1NCCC1)\NC Chemical compound CC(C)/N=C(/[C@H]1NCCC1)\NC GJKQGMCYPJTRFU-QMMMGPOBSA-N 0.000 description 1
- SMTGVGXOWGLTPJ-MDCLKSGNSA-N CC(C)C(CN(C[C@@H](C1)F)[C@@H]1c1ncc(-c2ccc(-c3cc4cc(-c5cnc([C@H](C[C@H](C6)F)N6C([C@H](C(C)C)NC(OC)=O)=O)[nH]5)ccc4[n]3[C@H](c(cc3)ccc3C(C=C3)=CC[C@@H]3c3ccccc3)O3)c3c2)[nH]1)NC(OC)=O Chemical compound CC(C)C(CN(C[C@@H](C1)F)[C@@H]1c1ncc(-c2ccc(-c3cc4cc(-c5cnc([C@H](C[C@H](C6)F)N6C([C@H](C(C)C)NC(OC)=O)=O)[nH]5)ccc4[n]3[C@H](c(cc3)ccc3C(C=C3)=CC[C@@H]3c3ccccc3)O3)c3c2)[nH]1)NC(OC)=O SMTGVGXOWGLTPJ-MDCLKSGNSA-N 0.000 description 1
- NROGULITEQPXPI-ILEVGNGJSA-N CC(C)[C@@H](C(N(C[C@@H](C1)F)[C@@H]1c1ncc(-c(cc2)cc(O[C@H](c(cc3)ccc3-c(cc3)ccc3-c3ccccc3)N3C4=CC5)c2C3=CC4=CC5c2cnc([C@H](C[C@H](C3)F)N3C([C@H](C(C)C)NOC)=O)[nH]2)[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)F)[C@@H]1c1ncc(-c(cc2)cc(O[C@H](c(cc3)ccc3-c(cc3)ccc3-c3ccccc3)N3C4=CC5)c2C3=CC4=CC5c2cnc([C@H](C[C@H](C3)F)N3C([C@H](C(C)C)NOC)=O)[nH]2)[nH]1)=O)NC(OC)=O NROGULITEQPXPI-ILEVGNGJSA-N 0.000 description 1
- CEFVHPDFGLDQKU-YFKPBYRVSA-N CC(C)[C@@H](C(O)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(O)=O)NC(OC)=O CEFVHPDFGLDQKU-YFKPBYRVSA-N 0.000 description 1
- ZIBQFRGEFBFLLS-UHFFFAOYSA-N CC(C1)C(C)=CC(O)=C1c1cc(cc(cc2)Br)c2[nH]1 Chemical compound CC(C1)C(C)=CC(O)=C1c1cc(cc(cc2)Br)c2[nH]1 ZIBQFRGEFBFLLS-UHFFFAOYSA-N 0.000 description 1
- LDWUFAAFJKZTDY-CALVRSAPSA-N CC(CCl)[C@@](C)(C=C)N/C(/[C@H](CC(C1)F)N1C(OC(C)(C)C)=O)=N\C=C Chemical compound CC(CCl)[C@@](C)(C=C)N/C(/[C@H](CC(C1)F)N1C(OC(C)(C)C)=O)=N\C=C LDWUFAAFJKZTDY-CALVRSAPSA-N 0.000 description 1
- DJIQDHXAMYMRRC-LURJTMIESA-N CC1(C)CN[C@H](CO)C1 Chemical compound CC1(C)CN[C@H](CO)C1 DJIQDHXAMYMRRC-LURJTMIESA-N 0.000 description 1
- TWOZIFDJLJAOSY-UHFFFAOYSA-N CC1(C)OB(c(cc2)cc(OC(CCc3ccccc3)[n]3c(cc4)c5cc4S4OC(C)(C)C(C)(C)O4)c2-c3c5Cl)OC1(C)C Chemical compound CC1(C)OB(c(cc2)cc(OC(CCc3ccccc3)[n]3c(cc4)c5cc4S4OC(C)(C)C(C)(C)O4)c2-c3c5Cl)OC1(C)C TWOZIFDJLJAOSY-UHFFFAOYSA-N 0.000 description 1
- UIWORXHEVNIOJG-UHFFFAOYSA-N CC1CCC(C)(C)CC1 Chemical compound CC1CCC(C)(C)CC1 UIWORXHEVNIOJG-UHFFFAOYSA-N 0.000 description 1
- BXYBSIWXCMTFOF-ZLOXHNJVSA-N CC1Oc2cc(-c3cnc(C4(C)C(CC5)CCC5CC4)[nH]3)ccc2-c2cc(cc(cc3)-c4cnc([C@H]5NCCC5)[nH]4)c3[n]12 Chemical compound CC1Oc2cc(-c3cnc(C4(C)C(CC5)CCC5CC4)[nH]3)ccc2-c2cc(cc(cc3)-c4cnc([C@H]5NCCC5)[nH]4)c3[n]12 BXYBSIWXCMTFOF-ZLOXHNJVSA-N 0.000 description 1
- VUDZAQBCBICTPL-VIFPVBQESA-N CCCCCOC([C@H](CC1(C)C)NC1=O)=O Chemical compound CCCCCOC([C@H](CC1(C)C)NC1=O)=O VUDZAQBCBICTPL-VIFPVBQESA-N 0.000 description 1
- MOVVHDSEFXQTPF-UHFFFAOYSA-N CCCN(CCC#C)Cc1cnc[nH]1 Chemical compound CCCN(CCC#C)Cc1cnc[nH]1 MOVVHDSEFXQTPF-UHFFFAOYSA-N 0.000 description 1
- BYDMIGIIZIMDDI-ZETCQYMHSA-N CCC[C@@H](CO)NCC Chemical compound CCC[C@@H](CO)NCC BYDMIGIIZIMDDI-ZETCQYMHSA-N 0.000 description 1
- UTIKFMIXRANERM-UHFFFAOYSA-N CCN(C)C(CC1CC1)OCC=C Chemical compound CCN(C)C(CC1CC1)OCC=C UTIKFMIXRANERM-UHFFFAOYSA-N 0.000 description 1
- YDTGGANOEGSCNE-UHFFFAOYSA-N C[BrH]c(cc1)cc(O)c1-c([nH]c(cc1)c2cc1Br)c2Cl Chemical compound C[BrH]c(cc1)cc(O)c1-c([nH]c(cc1)c2cc1Br)c2Cl YDTGGANOEGSCNE-UHFFFAOYSA-N 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Cc1ccccc1 Chemical compound Cc1ccccc1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N c1ccccc1 Chemical compound c1ccccc1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2010/077493 WO2012040923A1 (fr) | 2010-09-29 | 2010-09-29 | Dérivés d'indoles tétracycliques et leurs méthodes d'utilisation pour le traitement de maladies virales |
| CNPCT/CN2010/077493 | 2010-09-29 | ||
| US201061426724P | 2010-12-23 | 2010-12-23 | |
| US61/426,724 | 2010-12-23 | ||
| PCT/CN2011/001638 WO2012041014A1 (fr) | 2010-09-29 | 2011-09-28 | Dérivés d'indoles tétracycliques pour le traitement d'une infection par le virus de l'hépatite c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2013538831A true JP2013538831A (ja) | 2013-10-17 |
Family
ID=45891857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013530529A Withdrawn JP2013538831A (ja) | 2010-09-29 | 2011-09-28 | Ｃ型肝炎ウィルス感染治療のための四環式インドール誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2621931A4 (fr) |
| JP (1) | JP2013538831A (fr) |
| KR (1) | KR20140001879A (fr) |
| AU (1) | AU2011307953B2 (fr) |
| BR (1) | BR112013007696A2 (fr) |
| CA (1) | CA2811662A1 (fr) |
| MX (1) | MX2013003631A (fr) |
| WO (1) | WO2012041014A1 (fr) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190127365A1 (en) | 2017-11-01 | 2019-05-02 | Merck Sharp & Dohme Corp. | Inhibitors of hepatitis c virus replication |
| HUE036906T2 (hu) | 2009-05-13 | 2018-08-28 | Antivirális vegyületek | |
| UY32699A (es) | 2009-06-11 | 2010-12-31 | Abbott Lab | Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv"), procesos, composiciones, y métodos relacionados |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| JP2012533569A (ja) | 2009-07-16 | 2012-12-27 | ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド | フラビウイルス感染症を治療又は予防するためのベンゾイミダゾール類似体 |
| CN102869657A (zh) | 2010-03-24 | 2013-01-09 | 沃泰克斯药物股份有限公司 | 用于治疗或预防黄病毒感染的类似物 |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| US8859595B2 (en) | 2010-08-26 | 2014-10-14 | Rfs Pharma, Llc | Potent and selective inhibitors of hepatitis C virus |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| WO2013007106A1 (fr) | 2011-07-09 | 2013-01-17 | 广东东阳光药业有限公司 | Composés spiro en tant qu'inhibiteurs du virus de l'hépatite c |
| WO2013030750A1 (fr) | 2011-09-01 | 2013-03-07 | Lupin Limited | Composés antiviraux |
| KR101991298B1 (ko) | 2011-09-16 | 2019-06-21 | 길리애드 파마셋 엘엘씨 | Hcv 치료 방법 |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| SG11201404475TA (en) | 2012-02-10 | 2014-08-28 | Lupin Ltd | Antiviral compounds with a dibenzooxaheterocycle moiety |
| TWI610916B (zh) | 2012-08-03 | 2018-01-11 | 廣東東陽光藥業有限公司 | 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用 |
| TWI585082B (zh) | 2012-11-29 | 2017-06-01 | 廣東東陽光藥業有限公司 | 作爲丙型肝炎抑制劑的螺環化合物、藥物組合物及它們的用途 |
| US9802949B2 (en) | 2012-11-29 | 2017-10-31 | Sunshine Lake Pharma Co., Ltd. | Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof |
| WO2014110688A1 (fr) * | 2013-01-16 | 2014-07-24 | Merck Sharp & Dohme Corp. | Composés tétracycliques à substitution thiophène et leurs procédés d'utilisation pour le traitement des maladies virales |
| WO2014110687A1 (fr) * | 2013-01-16 | 2014-07-24 | Merck Sharp & Dohme Corp. | Composés tétracycliques substitués par thiazolyle et leurs procédés d'utilisation pour le traitement de maladies virales |
| WO2014120981A1 (fr) | 2013-01-31 | 2014-08-07 | Gilead Pharmasset Llc | Formulation de combinaison de deux composés antiviraux |
| WO2014121418A1 (fr) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Composés hétérocycliques tétracycliques et leurs méthodes d'utilisation pour le traitement de l'hépatite c |
| WO2014121417A1 (fr) * | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de l'hépatite c |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| CN104230946B (zh) * | 2013-06-06 | 2017-03-08 | 爱博新药研发(上海)有限公司 | 抑制丙肝病毒的化合物、药物组合物及其应用 |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| CN105530933B (zh) | 2013-07-17 | 2018-12-11 | 百时美施贵宝公司 | 用于治疗hcv的包含联苯衍生物的组合产品 |
| PL3038601T3 (pl) | 2013-08-27 | 2020-08-24 | Gilead Pharmasset Llc | Formulacja złożona dwóch związków przeciwwirusowych |
| EP3063145A4 (fr) * | 2013-10-30 | 2017-08-23 | Merck Sharp & Dohme Corp. | Procédé de préparation de composés hétérocycliques tétracycliques |
| WO2015089810A1 (fr) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Composés tétracycliques hétérocycliques condensés et leurs procédés d'utilisation pour le traitement de maladies virales |
| EP3089757A1 (fr) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Formes galéniques antivirales solides |
| CN104803989B (zh) | 2014-01-23 | 2017-12-22 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的桥环化合物及其在药物中的应用 |
| WO2016004899A1 (fr) * | 2014-07-11 | 2016-01-14 | Merck Sharp & Dohme Corp. | Procédé de préparation de composés hétérocycliques tétracycliques |
| US10457690B2 (en) | 2015-06-04 | 2019-10-29 | Merck Sharp & Dohme Corp. | Process for preparing substituted tetracyclic heterocycle compounds |
| US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2017097253A1 (fr) * | 2015-12-10 | 2017-06-15 | 正大天晴药业集团股份有限公司 | Dérivé d'elbasvir modifié par du deutérium, composition de médicament le contenant et son utilisation |
| WO2017181947A1 (fr) * | 2016-04-20 | 2017-10-26 | 深圳市塔吉瑞生物医药有限公司 | Carbamate substitué de diamine, composition pharmaceutique et application correspondante |
| WO2018032467A1 (fr) * | 2016-08-18 | 2018-02-22 | Merck Sharp & Dohme Corp. | Composés tétracycliques substitués par chromane et leurs utilisations dans le traitement de maladies virales |
| WO2018032468A1 (fr) * | 2016-08-18 | 2018-02-22 | Merck Sharp & Dohme Corp. | Composés tétracycliques substitués par hétérocycles et leurs procédés d'utilisation pour le traitement de maladies virales |
| RU2650610C1 (ru) | 2017-02-28 | 2018-04-16 | Васильевич Иващенко Александр | Противовирусная композиция и способ ее применения |
| RU2659388C1 (ru) | 2017-02-28 | 2018-07-02 | Васильевич Иващенко Александр | Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070049593A1 (en) * | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| US7745636B2 (en) * | 2006-08-11 | 2010-06-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7704992B2 (en) * | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2373168A4 (fr) * | 2008-12-03 | 2012-08-01 | Presidio Pharmaceuticals Inc | Inhibiteurs du virus de l'hépatite c de type ns5a |
| CN104163816A (zh) * | 2008-12-03 | 2014-11-26 | 普雷西迪奥制药公司 | Hcv ns5a的抑制剂 |
| GEP20146134B (en) * | 2009-03-27 | 2014-08-11 | Merck Sharp & Dohme | Inhibitors of hepatitis c virus replication |
-
2011
- 2011-09-28 BR BR112013007696A patent/BR112013007696A2/pt not_active IP Right Cessation
- 2011-09-28 AU AU2011307953A patent/AU2011307953B2/en not_active Expired - Fee Related
- 2011-09-28 EP EP11827912.4A patent/EP2621931A4/fr not_active Withdrawn
- 2011-09-28 KR KR1020137010717A patent/KR20140001879A/ko not_active Application Discontinuation
- 2011-09-28 JP JP2013530529A patent/JP2013538831A/ja not_active Withdrawn
- 2011-09-28 WO PCT/CN2011/001638 patent/WO2012041014A1/fr active Application Filing
- 2011-09-28 CA CA2811662A patent/CA2811662A1/fr not_active Abandoned
- 2011-09-28 MX MX2013003631A patent/MX2013003631A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MX2013003631A (es) | 2013-10-01 |
| AU2011307953B2 (en) | 2014-07-31 |
| EP2621931A4 (fr) | 2014-03-19 |
| CA2811662A1 (fr) | 2012-04-05 |
| KR20140001879A (ko) | 2014-01-07 |
| EP2621931A1 (fr) | 2013-08-07 |
| BR112013007696A2 (pt) | 2019-09-24 |
| WO2012041014A1 (fr) | 2012-04-05 |
| AU2011307953A1 (en) | 2013-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013538831A (ja) | Ｃ型肝炎ウィルス感染治療のための四環式インドール誘導体 | |
| US9504690B2 (en) | Tetracyclic xanthene derivatives and methods of use thereof for the treatment of viral diseases | |
| US9254292B2 (en) | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases | |
| JP6417380B2 (ja) | 複素環置換四環式化合物およびウイルス性疾患を治療するためのその使用法 | |
| WO2012040923A1 (fr) | Dérivés d'indoles tétracycliques et leurs méthodes d'utilisation pour le traitement de maladies virales | |
| WO2012041227A1 (fr) | Composés hétérocycliques tétracycliques pour le traitement d'une infection par le virus de l'hépatite c | |
| WO2012040924A1 (fr) | Composés hétérocycliques tétracycliques condensés et leurs méthodes d'utilisation pour le traitement de maladies virales | |
| JP2012528195A (ja) | Ｃ型肝炎などの疾患を処置するための３つの結合アリール部分で構成された抗菌性化合物 | |
| KR20130008040A (ko) | 융합된 트리시클릭 실릴 화합물 및 바이러스성 질환의 치료를 위한 그의 사용 방법 | |
| EP2598149A2 (fr) | Composés de biphénylène substitué et procédés d'utilisation desdits composés pour le traitement de maladies virales | |
| EP2945953A1 (fr) | Composés tétracycliques à substitution thiophène et leurs méhodes d'utilisation pour le traitement de maladies virales | |
| US10646494B2 (en) | Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases | |
| WO2018032467A1 (fr) | Composés tétracycliques substitués par chromane et leurs utilisations dans le traitement de maladies virales | |
| US20190002480A1 (en) | Silane-Containing Heterocyclic Compounds and Methods of Use Thereof for the Treatment of Viral Diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A300 | Application deemed to be withdrawn because no request for examination was validly filed |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 20141202 |